Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions

By Bredberg E.   Andersson T.B.   Frison L.   Thuresson A.   Johansson S.   Eriksson-Lepkowska M.   Larsson M.   Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 765-777

Adis International

Access to resources Recommend Favorite

Prediction and In Vitro Evaluation of Selected Protease Inhibitor Antiviral Drugs as Inhibitors of Carboxylesterase 1: A Potential Source of Drug-Drug Interactions

By Rhoades Jenna   Peterson Yuri   Zhu Hao-Jie   Appel David   Peloquin Charles   Markowitz John  

Pharmaceutical Research, Vol. 29, Iss. 4, 2012-04 ,pp. : 972-982

Springer Publishing Company

Access to resources Recommend Favorite

Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia

By Kostapanos Michael S.   Milionis Haralampos J.   Elisaf Moses S.  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 1, 2010-02 ,pp. : 11-28

Adis International

Access to resources Recommend Favorite

Are Circulating Metabolites Important in Pharmacokinetic Drug-Drug Interactions? A Retroanalysis of Clinical Data

By  

Current Drug Metabolism, Vol. 15, Iss. 8, 2014-01 ,pp. : 767-790

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Risk Management in Dutch Community Pharmacies: The Case of Drug-Drug Interactions

By Buurma Henk   De Smet Peter A.G.M   Egberts Antoine C.G.  

Drug Safety, Vol. 29, Iss. 8, 2006-01 ,pp. : 723-732

Adis International

Access to resources Recommend Favorite